GlaxoSmithKline on Thursday said that a pre-clinical analysis of the antibody-based Covid-19 therapy it is developing with US partner Vir has indicated that the drug also works against the new Omicron variant.
Further tests will be carried out on the sotrovimab therapy to firm up the results, GSK said in a statement.
Watch the latest DH Videos here:
(Published 02 December 2021, 08:59 IST)
JOIN US